Next Article in Journal / Special Issue
A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody–Drug Conjugates
Previous Article in Journal / Special Issue
Factors Affecting the Pharmacology of Antibody–Drug Conjugates
Article Menu

Export Article

Open AccessReview
Antibodies 2018, 7(1), 11; https://doi.org/10.3390/antib7010011

Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy

1
Mundipharma EDO GmbH, Basel CH-4020, Switzerland
2
Consultant, Cleveland Heights, OH 441188, USA
*
Author to whom correspondence should be addressed.
Received: 13 December 2017 / Revised: 7 February 2018 / Accepted: 9 February 2018 / Published: 13 February 2018
(This article belongs to the Special Issue Antibody Drug Conjugates)
View Full-Text   |   Download PDF [602 KB, uploaded 14 February 2018]   |  

Abstract

Although considerable progress has been made in the field of cancer chemotherapy, there remains a significant unmet medical need, with a requirement to move away from traditional cytotoxics and explore novel, smarter chemotherapeutic approaches. One such example of the smart chemotherapy approach is antibody-drug conjugates (ADCs), which consist of an antibody that binds selectively to a cancer antigen linked to a cytotoxic agent. When developing an ADC, it may be necessary to produce a variety of constructs to fully assess the optimal configuration for the molecule. By testing ADCs prepared using a range of cytotoxic agents, linkers, or different antibodies, it is possible to fully assess the optimal approach for this treatment modality before advancing to the clinic. Since the development and approval of first-generation ADCs, significant improvements in development technology have occurred. Here, we consider the advances made within the field of ADCs, focusing on the development of EDO-B278 and EDO-B776, both of which have demonstrated efficacy in preclinical testing. Although some limitations remain in this field of development, the potential reduction in toxicity offered by ADCs justifies the investment in research to find workable solutions that could ultimately provide patients with superior outcomes. View Full-Text
Keywords: antibody-drug conjugate; smart chemotherapy; targeted treatment; solid tumours; haematological malignancies antibody-drug conjugate; smart chemotherapy; targeted treatment; solid tumours; haematological malignancies
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Mehrling, T.; Soltis, D. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top